LON­DON— Over the past sev­er­al years, da­ta sci­en­tists search­ing through na­tion­al health records have no­ticed some­thing sur­pris­ing about peo­ple who had been vac­ci­nat­ed for...

Last sum­mer, ze­ro biotechs made it on­to the pub­lic mar­kets as the in­dus­try weath­ered a sev­en-month dry spell for ini­tial share sales. This time around...

Plus, news about Take­da, No­var­tis and Re­genxbio.

🤝 Mis­sion sells kid­ney in­jury drug to Dimer­ix: Dimer­ix will pay$5 mil­lion up­front for Mis­sion’s Phase 2-ready...

In a ma­jor stum­ble for GSK’s $2 bil­lion ac­qui­si­tion of Bel­lus Health, the UK phar­ma saidFri­day it is end­ing de­vel­op­ment of cam­lip­ix­ant in re­frac­to­ry...